{"classes":[{"categories":[{"measurements":[{"comment":"A median time to first new flare could not be estimated because \\<50% patients had a new flare during the time period.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"A median time to first new flare could not be estimated because \\<50% patients had a new flare during the time period.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"112"},{"groupId":"OG001","value":"114"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of time to first new flare and confidence intervals were determined. For patients with event, time to event = (date of event - date of first dose of study drug + 1). Patients met definition of new flare if they had: •Flare in joint, not a previously affected joint (at baseline or during study) •Flare in joint previously affected (at baseline or during study) after previous flare in joint has resolved completely. Patients did not meet criterion of having new gout flare if: • Increasing/renewed gout pain in an affected joint before flare has resolved completely.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG000","title":"Canakinumab 150 mg"},{"description":"Participants received 1 intramuscular injection of triamcinolone acetonide 40 mg and 1 sc injection of placebo to canakinumab on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose.","id":"OG001","title":"Triamcinolone Acetonide 40 mg"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS) consisted of all patients as randomized in the core study who had taken at least one dose of study drug.","reportingStatus":"POSTED","timeFrame":"Baseline to 12 weeks","title":"Time to First New Flare: Survival Analysis During the 12 Weeks of Study","type":"PRIMARY","unitOfMeasure":"Days"}